Follow-up Study of Autologous Adipose-derived Stem Cells (ANTG-ASC) for the Complex Fistula (ANTG-ASC-211)

Inclusion Criteria: * the patients who have participated in ANTG-ASC-210 clinical trial * the patients with complete closure at week 8 after last injection in ANTG-ASC-210 trials * the patients who submit written informed consents and is able to obey requirements of trials Exclusion Criteria: * a patient who has a history of variant Creutzfeldt Jacobs disease or related diseases * a patient who is allergic to anesthetics, bovine derived proteins or a fibrin glue * a patient who has an autoimmune disease * a patient who has infectious diseases such as hepatitis B virus (HBV), hepatitis C virus (HCV) or human immunodeficiency virus (HIV) * a patient who has a symptom of septicemia or active tuberculosis (contain tuberculosis of anus and rectum) * a patient who is pregnant or breast feeding * a patient who is not willing to use effective contraceptive methods during the study * a patient who has inflammatory Bowel disease * a patient who is sensitive to fibrin glue * a patient who have a clinically relevant history of abuse of alcohol or drugs, habitual smoker (who smoked more than 20 cigarettes a day) * a patient who is not able to understand the objective of this study or to comply with the study requirements * a patient who is considered to have a significant disease which can impact the study by investigator * a patient who is considered not suitable for the study by investigator * a patient who had a history of surgery for malignant tumor within the last five years (except carcinoma in situ) * a patient who has multisystemic wasting syndrome (such as tuberculosis, Diabetes, Thyroid disorders, tumor, etc.) * a patient who has taken cytotoxic drugs (such as immunosuppressants, corticosteroid, cytotoxic chemotherapy, anticoagulants, etc.) during long-term